JPH09124507A5 - - Google Patents

Info

Publication number
JPH09124507A5
JPH09124507A5 JP1996265084A JP26508496A JPH09124507A5 JP H09124507 A5 JPH09124507 A5 JP H09124507A5 JP 1996265084 A JP1996265084 A JP 1996265084A JP 26508496 A JP26508496 A JP 26508496A JP H09124507 A5 JPH09124507 A5 JP H09124507A5
Authority
JP
Japan
Prior art keywords
solution
ionic strength
concentration
activity
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1996265084A
Other languages
English (en)
Japanese (ja)
Other versions
JP4036494B2 (ja
JPH09124507A (ja
Filing date
Publication date
Priority claimed from US08/532,211 external-priority patent/US6686191B1/en
Application filed filed Critical
Publication of JPH09124507A publication Critical patent/JPH09124507A/ja
Publication of JPH09124507A5 publication Critical patent/JPH09124507A5/ja
Application granted granted Critical
Publication of JP4036494B2 publication Critical patent/JP4036494B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP26508496A 1995-09-22 1996-09-17 ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製 Expired - Lifetime JP4036494B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/532,211 US6686191B1 (en) 1995-09-22 1995-09-22 Preparation of virally inactivated intravenously injectable immune serum globulin
US532211 1995-09-22

Publications (3)

Publication Number Publication Date
JPH09124507A JPH09124507A (ja) 1997-05-13
JPH09124507A5 true JPH09124507A5 (enExample) 2004-09-02
JP4036494B2 JP4036494B2 (ja) 2008-01-23

Family

ID=24120836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26508496A Expired - Lifetime JP4036494B2 (ja) 1995-09-22 1996-09-17 ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製

Country Status (10)

Country Link
US (1) US6686191B1 (enExample)
EP (2) EP1356829A3 (enExample)
JP (1) JP4036494B2 (enExample)
AT (1) ATE257016T1 (enExample)
AU (1) AU709608B2 (enExample)
CA (1) CA2185859C (enExample)
DE (1) DE69631229T2 (enExample)
DK (1) DK0764447T3 (enExample)
ES (1) ES2213760T3 (enExample)
PT (1) PT764447E (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044948A2 (en) * 1997-04-07 1998-10-15 Cangene Corporation Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
BR9807936A (pt) 1997-04-08 2000-02-22 Baxter Ag Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação
US6717116B1 (en) * 1999-08-10 2004-04-06 Ibiden Co., Ltd. Semiconductor production device ceramic plate
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
KR100791502B1 (ko) * 2006-09-29 2008-01-03 한스바이오메드 주식회사 바이러스 불활화된 무세포 인체 이식재 생산방법
EP2077118A1 (en) * 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Clottable concentrate of platelet growth factors and preparation method thereof
TW201039854A (en) 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
LT3345615T (lt) 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN102357259A (zh) * 2011-07-28 2012-02-22 王珊珊 一种生物蛋白海绵及其制备方法
EP3981873A1 (en) 2012-06-29 2022-04-13 EMD Millipore Corporation Methods for inactivating viruses during a protein purification process
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4762714A (en) * 1986-04-08 1988-08-09 Miles Laboratories, Inc. Preparation of retrovirus-free immunoglobulins
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
EP0523406B1 (en) * 1991-07-05 1998-12-09 Bayer Corporation Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity

Similar Documents

Publication Publication Date Title
JPH09124507A5 (enExample)
Brier et al. Inhibition or enhancement of immunological injury of virus-infected cells
Oldstone et al. Immune complex disease in chronic viral infections
ES515177A0 (es) Procedimiento para el tratamiento de inmunoglobulina de suero.
US4849508A (en) Pasteurization of immunoglobulin solutions
NO924279L (no) Lyofilisert, monoklonalt antistoffpreparat
DE58905514D1 (de) Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen immunoglobulin-Präparates mit hohemIgM-Gehalt.
CA2185859A1 (en) Preparation of virally inactivated intravenously injectable immune serum globulin
GB1488774A (en) Hepatitis b antigen and method of producing it
AU6067896A (en) Immunoglobulin for treatment of respiratory syncytial virus
Nielsen et al. Effect of host decomplementation on homeostasis of antibody production in fowl
NZ334885A (en) Method for producing an igm preparation for intravenous administration
CA2063303A1 (en) Preparation of virus-free immunoglobulins
McCans et al. Effects of an antibody to a highly purified Na+, K+-ATPase from canine renal medulla: Separation of the “holoenzyme antibody” into catalytic and cardiac glycoside receptor-specific components
Ahmad et al. A novel method for immobilization of chicken brain arylsulfatase A using concanavalin A
Heijtink et al. Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre‐treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes
Goodman et al. Neutralization of bacteriophage by intact and degraded rabbit antibody
JPS5615215A (en) Preparation of human immunoglobulin for intravenous injection with immobilized pepsin gel
DE1792555A1 (de) Verfahren zur Herstellung von zur intravenoesen Anwendung geeignetem gamma-Globulin
Coulson et al. Ribonuclease of bovine milk: Serological relationship to pancreatic ribonuclease
JPS567721A (en) Preparation of immunoglobulin for intravenous injection
Horowitz et al. Elimination of disease-transmitting enveloped viruses from human blood plasma and mammalian cell culture products: Assurance of virus safety of biological products.
SU780261A1 (ru) Способ определени термолабильных вирусотропных ингибиторов
SU736978A1 (ru) Способ получени иммунной асцитической жидкости
KATsUNo et al. On the Characteristics of Anti-Br. abortus Strain 19 Agents in Albumin and Globulin Fractions